In pharmaceutical and biotechnology patent examination, applicants may sometimes submit supplementary experimental data after the filing date to support the technical effects relied upon during examination. However, such data does not form part of the specification as filed and may be accepted only as evidentiary support under certain conditions.
Under the relevant examination principles, supplementary experimental data may be considered only where:
The following examples illustrate how these principles may apply in practice.
Example 1: Enzyme-inhibition effect already disclosed and experimentally supported
The description discloses that a group of aminopyridine derivatives exhibits acetylcholinesterase (AChE) inhibitory activity and explains that AChE inhibition may improve memory. The specification provides in vitro data for representative compounds A1 and A2 and refers to in vivo testing systems for evaluating memory improvement in mice.
After filing, the applicant submits additional in vivo data showing the memory-improvement effect in mice, together with dose-response curves comparing the results with the prior art.
Because both the relevant technical effects and the corresponding testing methods were already disclosed in the original description, the supplementary data merely substantiates those effects in comparison with the prior art. The supplementary data is therefore accepted as evidence for demonstrating inventive step.
Example 2: Supplementary data for formulation stability
The description discloses a tablet containing active ingredient B and PVP to improve storage stability, stating that stability is improved compared with a formulation without PVP. However, no experimental data or details of the testing system are provided.
The applicant subsequently submits stability data showing the active-ingredient content after six months at 40°C/75% RH.
Although “improved stability” is mentioned in the original description, the specification does not adequately disclose the experimental basis for this effect, including the tested substance or mixture, testing method, test article and control, test conditions, or results.
Accordingly, the original description does not satisfy the requirements of sufficiency of disclosure, clarity, and enablement. The supplementary data is therefore not accepted.
Example 3: Supplementary data establishing a new therapeutic effect
The description discloses that compound C is a tyrosine kinase inhibitor with a therapeutic effect against lung cancer and provides corresponding in vitro test results.
After filing, the applicant submits additional data showing that compound C also strongly inhibits the proliferation of breast cancer cells.
The therapeutic effect against breast cancer, however, was neither disclosed nor suggested in the original specification. The supplementary data therefore introduces a new therapeutic effect rather than merely substantiating an effect already disclosed.
Supplementary experimental data is consequently not considered, as it goes beyond the technical content of the specification as filed.
Key takeaway
These examples demonstrate that supplementary experimental data cannot be used to remedy insufficient disclosure or introduce a new technical effect after filing. Its role is limited to providing evidentiary support for a technical effect that was already adequately disclosed in the original specification.
For pharmaceutical and biotechnology patent applications, applicants should ensure that the original specification contains sufficient technical information-including relevant testing methods, experimental systems, and technical effects. Supplementary data may subsequently strengthen the evidentiary basis for that effect, particularly in the assessment of inventive step, but it cannot remedy insufficient disclosure or introduce a new technical effect.
+012 345 6789
info@example.com
123 Street, New York, USA